Eli Lilly says the company’s new oral pill helped maintain weight loss in patients switching away from injectable GLP-1 drugs. The medication is currently awaiting U.S. regulatory approval, which is expected early next year. Katherine Ward has this story and more in Health Matters for Dec. 18, 2025.
